Joint (NASDAQ:JYNT – Free Report) had its target price decreased by Roth Mkm from $16.00 to $15.00 in a research report sent to investors on Friday,Benzinga reports. Roth Mkm currently has a buy rating on the stock.
Separately, StockNews.com lowered shares of Joint from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th.
Read Our Latest Stock Report on JYNT
Joint Stock Performance
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Verus Capital Partners LLC raised its position in Joint by 5.9% in the third quarter. Verus Capital Partners LLC now owns 132,955 shares of the company’s stock valued at $1,521,000 after purchasing an additional 7,440 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Joint by 13.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 89,964 shares of the company’s stock valued at $1,029,000 after buying an additional 10,641 shares during the period. Squarepoint Ops LLC acquired a new position in Joint during the 2nd quarter worth approximately $144,000. Clayton Partners LLC boosted its holdings in Joint by 38.1% in the 2nd quarter. Clayton Partners LLC now owns 186,500 shares of the company’s stock worth $2,622,000 after acquiring an additional 51,500 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Joint in the second quarter valued at approximately $174,000. Hedge funds and other institutional investors own 76.88% of the company’s stock.
Joint Company Profile
The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Further Reading
- Five stocks we like better than Joint
- Stock Dividend Cuts Happen Are You Ready?
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Profitably Trade Stocks at 52-Week Highs
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- What Are Dividend Achievers? An Introduction
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.